Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 108

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

Naveen Pemmaraju, Luca Mazzarella, Giovanni Marconi, David Sallman, Matthew Ulrickson, Roland Walter, Valerio Maisano, Breanne Fishman, Yining Du, Jalaja Potluri, Hagop Kantarjian, Naval Daver

Blood (2025) 146 (Supplement 1): 5195.

https://doi.org/10.1182/blood-2025-5195

Published: 2025

Journal Articles

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)

Naval Daver, Andrew Sochacki, Monzr M. Al Malki, Eunice Wang, Marianna Muller, Anne Bellon, Sandrine Micallef, David Sallman, Karilyn Larkin

Blood (2025) 146 (Supplement 1): 5194.

https://doi.org/10.1182/blood-2025-5194

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg, Richard Stone, Eric Padron, David Sallman, Curtis Lachowiez, Jonathan Abbas, Abhishek Mangaonkar, Mrinal Patnaik, Marissa Timothy, Alonzo Martinez, Ewelina Morawa, Brandon Turunen, Philip Vickers, Sergio Santillana

Blood (2025) 146 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2025-3874

Published: 2025

Journal Articles

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

Zhuoer Xie, Qianxing Mo, Sarah Buckley, David Sallman, Jeffrey Lancet, Michael Savona, Rami Komrokji, Mrinal Patnaik, Daniel Wiseman, Eric Padron

Blood (2025) 146 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2025-3873

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Steven Tessier, Najla Al Ali, Michael Trinh, Andrew Brunner, Diletta Fontana, Carlo Gambacorti-Passerini, Rocco Piazza, David Sallman, Eric Padron, Zhuoer Xie, James Foran, Cecilia Arana Yi, Hassan Alkhateeb, Mithun Shah, Rami Komrokji, Aref Al-Kali

Blood (2025) 146 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2025-3864

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Kendra Sweet, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3856.

https://doi.org/10.1182/blood-2025-3856

Published: 2025

Journal Articles

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Abigail Huetteman, Najla Al Ali, David Sallman, Eric Padron, Andrew Kuykendall, Onyee Chan, Zhuoer Xie, Alison Walker, Seongseok Yun, Samuel Reynolds, Kendra Sweet, Rami Komrokji, Jeffrey Lancet

Blood (2025) 146 (Supplement 1): 3853.

https://doi.org/10.1182/blood-2025-3853

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Rami Komrokji, Amin Azem, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Samuel Reynolds, Seongseok Yun, Alison Walker, Kendra Sweet, Andrew Kuykendall, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 3851.

https://doi.org/10.1182/blood-2025-3851

Published: 2025

Journal Articles

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Blood (2025) 146 (Supplement 1): 3847.

https://doi.org/10.1182/blood-2025-3847

Published: 2025

Journal Articles

Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

Blood (2025) 146 (Supplement 1): 3840.

https://doi.org/10.1182/blood-2025-3840

Published: 2025

Journal Articles

IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease

Blood (2025) 146 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2025-3169

Published: 2025

Journal Articles

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami Komrokji, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Kendra Sweet, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 2072.

https://doi.org/10.1182/blood-2025-2072

Published: 2025

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm

Nana Adjoa Ben-Crentsil, Somedeb Ball, Hannah Newman, Christopher Ryder, Surendra Neupane, Anthony Hunter, Yu-Hung Wang, Kiran Batta, Kristian Gurashi, Traci Kruer, Maria Balasis, Ariel Quintana, Rami Komrokji, David Sallman, Andrew Kuykendall, Tracy George, Daniel Wiseman, Eric Padron

Blood (2025) 146 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2025-3763

Published: 2025

Journal Articles

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Blood (2025) 146 (Supplement 1): 768.

https://doi.org/10.1182/blood-2025-768

Published: 2025

Journal Articles

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Blood (2025) 146 (Supplement 1): 930.

https://doi.org/10.1182/blood-2025-930

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and safety of pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm in patients with prior or concomitant hematologic malignancy: Results from the cadenza study

A phase 1/2, first-in-human, multicenter, open-label trial evaluating the safety, tolerability, and antileukemic activity of Debio 1562M in patients with recurrent refractory acute myeloid leukemia (AML)

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Prospera (ABNL-MARRO 002): A randomized phase 2 study of pacritinib vs. hydroxyurea in patients with advanced proliferative chronic myelomonocytic leukemia (CMML)

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only